News

KNX Products Market Sees 13% CAGR Through 2030 | Rising Demand in Smart Residential & Commercial Buildings | Valuates Reports
The Global KNX Products Market is projected to grow from USD 6653.8 Million in 2024 to USD 13850 Million by 2030, at a ...
The Manila Times18m
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
(NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with ...
Sanofi Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch ...
UGI: This Dividend Aristocrat Is Outperforming And Undervalued
UGI Corporation stands out among Dividend Aristocrats with solid earnings, attractive valuation, and strong dividend history ...
The Manila Times18m
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria . Approval based on phase 3 studies demonstrating Dupixent signifi ...